IP6K2

IP6K2 is an inositol hexakisphosphate kinase that generates 5-PP-InsP5 (5-IP7), a signaling pyrophosphate that controls cell-fate decisions spanning apoptosis, proliferation, phosphate homeostasis, and tissue morphogenesis. IP6K2 promotes apoptosis through multiple convergent mechanisms: its product 5-IP7 activates CK2-dependent phosphorylation of the TTT cochaperone complex to stabilize DNA-PKcs/ATM and drive p53 Ser-15 phosphorylation (PMID:24657168); IP6K2 directly binds p53 to shift transcriptional output from cell-cycle arrest toward apoptosis (PMID:21078964); and it inhibits NF-κB survival signaling by binding TRAF2 and blocking TAK1 phosphorylation (PMID:17379600). Beyond apoptosis, IP6K2 acts as a positive regulator of Hedgehog signaling downstream of Smoothened (PMID:20980661), controls phosphate export via XPR1 and renal NaPi-IIa/IIc cotransporter expression (PMID:31186349, PMID:38317282), promotes E-cadherin endocytosis by inhibiting OCRL to elevate PI(4,5)P2 at adherens junctions (PMID:40858937), and regulates mitochondrial energy homeostasis through its interaction with creatine kinase-B and a catalytically independent attenuation of PINK1-mediated mitophagy (PMID:33547244, PMID:35353626).

1. 2001 High

   Establishing IP6K2 as a pro-apoptotic kinase answered whether inositol pyrophosphate metabolism was linked to programmed cell death: IFN-β post-transcriptionally induces IP6K2, and its catalytic activity is required for IFN-β-induced apoptosis.

   Evidence Antisense knockdown and kinase-dead mutant expression in ovarian carcinoma cells with apoptosis readouts

   PMID:11337497

   Open questions at the time

   • Downstream mediators of IP6K2-driven apoptosis were unknown
   • Whether 5-IP7 itself or another product mediated the effect was unresolved
2. 2002 Medium

   Identifying the extrinsic death receptor pathway as a downstream effector placed IP6K2 upstream of DR4/DR5 and caspase-8 in apoptosis signaling.

   Evidence Overexpression in ovarian carcinoma cells; blocking by dominant-negative DR5 and Bcl-2

   PMID:11896621

   Open questions at the time

   • Reliance on overexpression without loss-of-function confirmation
   • Whether endogenous IP6K2 levels are sufficient to engage DR4/DR5 was untested
3. 2005 High

   Demonstrating IFN-β-induced nuclear translocation of IP6K2 and its requirement for apoptosis resolved where in the cell IP6K2 must act to execute its death-promoting function.

   Evidence IP6K2-eGFP fusion imaging and NLS point mutant expression in apoptosis assays

   PMID:15634191

   Open questions at the time

   • Nuclear substrates or binding partners mediating apoptosis were unidentified
   • Whether catalysis occurs in the nucleus or whether nuclear localization serves a scaffolding role was unclear
4. 2007 High

   Discovery that IP6K2 binds TRAF2 and inhibits TAK1/NF-κB signaling revealed a second mechanism through which IP6K2 shifts cell fate toward apoptosis — by suppressing pro-survival NF-κB.

   Evidence Co-immunoprecipitation, S347A/S359A mutagenesis, TAK1 phosphorylation and NF-κB DNA binding assays

   PMID:17379600

   Open questions at the time

   • Whether this requires catalytic activity or is a scaffolding function was not dissected
   • In vivo relevance of the TRAF2 interaction was not tested
5. 2008 High

   Identifying HSP90 as a physical inhibitor of IP6K2 catalytic activity established a tonic brake on IP6K2 and explained how HSP90 inhibitors trigger cell death — by unleashing IP6K2.

   Evidence Reciprocal Co-IP, in vitro kinase assay, HSP90 inhibitor treatment, mutagenesis

   PMID:18195352

   Open questions at the time

   • Whether HSP90 regulates IP6K2 stability in addition to activity was unresolved
   • Structural basis of HSP90-IP6K2 interaction was unknown
6. 2009 High

   IP6K2 knockout mice provided in vivo confirmation that IP6K2 is a tumor suppressor: KO animals show increased carcinogen susceptibility, and direct microinjection of 5-IP7 induces cell death, proving the product — not the enzyme per se — mediates apoptosis.

   Evidence IP6K2 knockout mice, carcinogen-induced tumor model, microinjection of 5-PP-InsP5

   PMID:19430495

   Open questions at the time

   • The paradoxical radiation resistance and accelerated DNA repair in KO mice remained mechanistically unexplained
   • Whether compensatory IP6K1/3 activity confounds phenotypes was not addressed
7. 2010 High

   Two advances linked IP6K2 to specific signaling pathways: direct binding to p53 shifts its transcriptional output from arrest to apoptosis, and genetic epistasis in zebrafish placed IP6K2 downstream of Smoothened in Hedgehog signaling.

   Evidence IP6K2 KO in HCT116 cells with p53 apoptosis/arrest readouts and Co-IP (p53); morpholino knockdown in zebrafish with Hh pathway epistasis (Hedgehog)

   PMID:20980661 PMID:21078964

   Open questions at the time

   • How IP6K2 binding alters p53 target gene selectivity at the chromatin level was unknown
   • The Hedgehog mechanism lacked identification of a direct IP6K2/IP7 target between Smoothened and Gli1
8. 2011 High

   CK2-mediated phosphorylation of IP6K2 PEST residues triggers its ubiquitination and proteasomal degradation, revealing a feedback loop: CK2 activity promotes survival by eliminating the pro-apoptotic kinase.

   Evidence In vitro CK2 phosphorylation, mutagenesis of Ser-347/Ser-356, ubiquitination assay, metabolic stability

   PMID:21262846

   Open questions at the time

   • The specific E3 ubiquitin ligase was not identified
   • Whether CK2-mediated degradation is stimulus-regulated was untested
9. 2014 High

   Reconstitution of a 5-IP7→CK2→TTT→DNA-PKcs/ATM→p53-Ser15 cascade provided the first complete biochemical pathway from IP6K2 catalytic product to p53 activation, while structural analysis revealed the substrate-binding clamshell geometry of the IP6K family.

   Evidence In vitro CK2 kinase assay with IP7, Co-IP, cell-based epistasis (signaling cascade); X-ray crystallography of Entamoeba IP6K, human IP6K2 modeling and mutagenesis (structure)

   PMID:24657168 PMID:24956979

   Open questions at the time

   • A high-resolution structure of human IP6K2 itself was still lacking
   • Whether CK2 activation by IP7 is selective to IP6K2-derived pools vs. IP6K1-derived pools was not resolved
10. 2015 High

    Demonstrating that IP6K2/IP7 promotes tumor metastasis via nuclear sequestration and inactivation of LKB1 revealed a pro-tumorigenic face of IP6K2, contrasting its well-established tumor-suppressive apoptotic role.

    Evidence Cell migration/invasion assays, IP6K2 knockdown, LKB1 localization, in vivo metastasis model

    PMID:25617365

    Open questions at the time

    • How 5-IP7 mechanistically drives LKB1 nuclear sequestration was not biochemically defined
    • Context-dependent switching between tumor-suppressive and pro-metastatic roles was unexplained
11. 2018 High

    Identification of protein 4.1N as a high-affinity IP6K2 partner linked IP6K2 to cerebellar function: IP6K2 controls 4.1N nuclear translocation, and their interaction regulates Purkinje cell morphology and locomotor behavior.

    Evidence Reciprocal Co-IP, IP6K2 KO mice, cerebellar immunofluorescence, locomotor behavioral tests

    PMID:30006360

    Open questions at the time

    • Whether the 4.1N interaction requires IP6K2 catalytic activity was not tested
    • Downstream nuclear targets of 4.1N were unknown
12. 2019 High

    Demonstrating that IP6K1/2-generated inositol pyrophosphates bind the SPX domain of XPR1 and control phosphate export established IP6K2 as a regulator of cellular phosphate homeostasis.

    Evidence CRISPR double KO of IP6K1/2 in HCT116, HPLC/PAGE IP7/IP8 profiling, 32Pi flux, SPX domain binding assay

    PMID:31186349

    Open questions at the time

    • Individual contributions of IP6K1 vs. IP6K2 to XPR1 regulation were not separated
    • In vivo phosphate phenotypes of IP6K2-single KO were not reported in this study
13. 2021 High

    Discovery that IP6K2 associates with creatine kinase-B and that IP6K2 KO cerebella show depleted phosphocreatine/ATP and elevated ROS established a bioenergetic function for IP6K2 in neuroprotection.

    Evidence Proteomic pull-down/MS, Co-IP, metabolite quantification, IP6K2 KO mice, rescue with N-acetylcysteine and phosphocreatine

    PMID:33547244

    Open questions at the time

    • Whether IP6K2 enzymatic activity or a scaffolding role underlies the CK-B interaction was unresolved
    • Mechanism linking IP6K2-CK-B to cytochrome c1/complex III expression was unclear
14. 2022 High

    Demonstrating that both wild-type and kinase-dead IP6K2 attenuate PINK1-dependent mitophagy in a PINK1-epistatic manner uncovered a catalytically independent, non-canonical function of IP6K2 in mitochondrial quality control.

    Evidence IP6K2 knockdown and kinase-dead rescue, PINK1 double-KD epistasis, mitophagy marker Western blots

    PMID:35353626

    Open questions at the time

    • Direct physical interaction between IP6K2 and PINK1 was not shown
    • Whether the non-catalytic mechanism involves a scaffolding surface or protein-protein interaction domain was undetermined
15. 2023 Medium

    Multiple studies expanded IP6K2's tissue-specific roles: IP6K2 is the dominant IP7 source in enteric neurons and regulates enteric nervous system gene programs; IP6K2-derived IP7 modulates nucleolar granular region architecture; and an allosteric inhibitor pocket was mapped by HDX-MS.

    Evidence IP6K2-KO mice with gut LC-MS IP7 profiling and transcriptomics (enteric); confocal imaging with WT vs. kinase-dead IP6K2 (nucleolus); analog-sensitive kinase screen with HDX-MS (allosteric pocket)

    PMID:36671538 PMID:36681123 PMID:37843983

    Open questions at the time

    • Enteric neuron phenotypes were transcriptomic without functional neuronal assays
    • Nucleolar mechanism proposed as electrostatic bridging but not biochemically reconstituted
    • Allosteric inhibitor tested only on gatekeeper mutant, not wild-type IP6K2
16. 2024 High

    Renal tubular-specific IP6K1/2 knockout revealed that IP6K2-derived 5-IP7 is essential for NaPi-IIa/IIc expression and renal phosphate reabsorption, with KO mice developing hypophosphatemia and secondary bone/mineral phenotypes.

    Evidence Conditional renal tubular Ip6k1/2-KO mice, brush border membrane vesicle phosphate uptake, plasma metabolite measurements

    PMID:38317282

    Open questions at the time

    • Individual contribution of IP6K2 vs. IP6K1 in the renal tubule was not dissected
    • Mechanism by which 5-IP7 regulates NaPi-IIa/IIc expression (transcriptional vs. post-translational) was not defined
17. 2025 High

    A ROS→Src→IP6K2→5-IP7⊣OCRL→PI(4,5)P2→E-cadherin endocytosis axis was delineated in colorectal cancer, and intestinal epithelium-specific IP6K2 deletion attenuated colitis-associated carcinogenesis, establishing IP6K2 as a druggable node in junction remodeling.

    Evidence In vitro kinase assay, OCRL binding-deficient mutant, PI(4,5)P2 measurement, conditional KO mice in DSS colitis model, IP6K2-selective inhibitor

    PMID:40858937

    Open questions at the time

    • Whether OCRL inhibition by 5-IP7 is direct or mediated by an intermediate was not fully resolved
    • Specificity of the IP6K2-selective inhibitor in vivo was not comprehensively profiled

• Key unresolved questions include: the high-resolution structure of human IP6K2, how IP6K2 switches between tumor-suppressive and pro-metastatic outputs in different cellular contexts, the identity of the E3 ligase mediating CK2-dependent IP6K2 degradation, and how IP6K2's catalytic and non-catalytic functions are coordinately regulated.
• No crystal structure of full-length human IP6K2
• E3 ubiquitin ligase for IP6K2 degradation unidentified
• Context-dependent switch between pro-apoptotic and pro-metastatic roles is mechanistically unexplained